Abastract ;
Preeclampsia (PE) is one of the leading causes of prenatal and maternal deaths; therefore developing new biomarkers at the earliest stages of illness is essential to accelerating effectiveness. Using serum microRNA 149 and copeptin to diagnose preeclampsia will be investigated in this study. We conducted a matched case–control study in Egyptian women. Seventy women between 28 and 40 weeks of pregnancy participated in the study and divided into two groups: 20 pregnant women without PE and 50 with PE. Blood biochemical parameters were assessed for all subjects in addition to genetic analysis for microRNA 149 was detected by RT-PCR. Serum copeptin was detected by ELISA. The present study demonstrated that ; preeclamptic patients had considerably lower serum levels of miR-149 than control cases at (p≤0.01). Meanwhile, preeclamptic patients had considerably higher serum levels of copeptin than controls at (p≤0.01). Serum copeptin levels may provide early indicators of preeclampsia.